COVID-19: A French study confirms effectiveness of vaccines on more than 22 million people

The authors show, on the largest population studied in the world, that the subjects vaccinated by 50 years and over have nine times less risk of being hospitalized or dying of SARS-COV-2 than non-vaccinated. That, up to five months after receiving a second dose.


The confirmation of the magnitude of the effectiveness of vaccination, in France, will she succeed to flex the last square of the undecis? “People vaccinated 50 years and over have nine times less risk of being hospitalized or dying of COVID-19 that non-vaccinated”, summarize the authors of two reports published on Monday, October 11 by Epi-Phare, a group of Scientific interest placed under the double guardianship of the National Medicine Safety Agency (ANSM) and the National Health Insurance Fund (CNAM).

The authors analyzed the effects of the three main vaccines that are or were used in France, Comirnaty (Pfizer), Spikevax (Moderna) and Vaxzevria (Astrazeneca). “In real living conditions, these three vaccines show comparable and very high efficiency, on a very important number of people. That, regardless of age from 50 years old. In addition, this efficiency is maintained in time , without showing down the four to five months of follow-up, “summarizes Mahmoud Zureik, director of EPI-Phare and professor of epidemiology and public health at the University of Versailles-Saint-Quentin (Yvelines).

Unprecedented, these two analyzes were carried out on a total of 22.6 million people. These are “epidemiological studies analyzing” real life “efficiency of vaccines that focus on the largest number of people in the world,” says Antoine Flahault, an epidemiology and director of the Global Health Institute in Geneva . “Israeli studies on the subject, they included nearly 6.5 million participants, the British Studies 2.6 million and North American Studies 3.4 Million,” says the Swiss epidemiologist.

These two studies confirm the effectiveness of clinical trials already carried out with these three vaccines, under very controlled conditions, remote from real life. Above all, they confirm Data already published on the impact of prevention campaigns in Israel (Haas E. et al, The Lancet, May 5, 2021), North America and the United Kingdom. In any case, the effectiveness of vaccines on serious forms and on CVIV-19 deaths was around 90% to 97%.

Sophisticated but proven mathematical analyzes

“Once the clinical trials are completed, the convergence of their results with those of” observational “epidemiological studies is very important,” says Antoine Flahault. These two studies are therefore “reinforcing the conviction of epidemiologists of the very high efficiency of these three vaccines on serious forms”. In May already, a first EPI-Phare study, carried out over more than four million people, had shown that people aged 75 and over, vaccinated between December 27, 2020 and February 24, had nine times less risk to be hospitalized for Covid-19 that non-vaccinated. This first analysis, however, did not include 50-75 years old.

You have 58.47% of this article to be read. The rest is reserved for subscribers.

/Media reports.